ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018
Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treatJAC-antimicrobial resistance · 2026Article
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular evolution and mechanisms underlying extremely high-level carbapenem resistance in the emerging CRPA clone ST1976.BMC microbiology · 2026Article
- Genomic and Phenotypic Insights into Carbapenem-ResistantMicroorganisms · 2026Article
- Temporal Trends and Mortality of Vancomycin-ResistantPathogens (Basel, Switzerland) · 2026Observational
- Co-occurrence of blaBMC microbiology · 2026Article
- Prevalence and effective treatment of drug-resistant Pseudomonas aeruginosa biofilm using flavonoid naringin.Bioprocess and biosystems engineering · 2025Article
- Evolution of Resistant Mutants inMicroorganisms · 2025Article
- Mortality and exacerbations in bronchiectasis patients with carbapenem-resistant Pseudomonas aeruginosa isolation: a long-term retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2025Article
- Epidemiological and genetic characteristics of clinical carbapenemase-producing Enterobacterales isolates from Batna hospitals in Algeria.BMC infectious diseases · 2024Article
- Characterization of carbapenem-resistant Enterobacterales andJournal of clinical microbiology · 2024Article
- Emergence of NDM-1-ProducingMicroorganisms · 2024Article
- Characterization of a novel multi-resistant Pseudomonas juntendi strain from China with chromosomal blaBMC genomics · 2024Article
- Hospital and municipal wastewater as a source of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in the environment: a review.Environmental science and pollution research international · 2024Review
- Carbapenem-ResistantMicroorganisms · 2023Article
- Replacement of the Double Meropenem Disc Test with a Lateral Flow Assay for the Detection of Carbapenemase-Producing Enterobacterales andAntibiotics (Basel, Switzerland) · 2023Article
- Molecular characterization and differential effects of levofloxacin and ciprofloxacin on the potential for developing quinolone resistance among clinicalFrontiers in microbiology · 2023Article
- The Intriguing Carbapenemases ofThe Yale journal of biology and medicine · 2022Review
- Occurrence and Characteristics of ESBL- and Carbapenemase- ProducingMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is an endemic problem in certain countries including Greece. CRPA and multidrug-resistant P. aeruginosa (MDRPA) firstly emerged in our region during the 80s, right after the launch of imipenem and meropenem as therapeutic agents against P. aeruginosa infections. The role of outer membrane protein (Opr) inactivation has been known to contribute to imipenem resistance since many years, while efflux overexpression systems have been mainly associated with meropenem resistance. Among carbapenemases, metallo-β-lactamases (MBL) and mostly Verona integron-mediated (VIM) MBL's have played the most crucial role in CRPA emergence. VIM-2 and VIM-4 producing CRPA, usually belonging to clonal complexes (CC) 111 and 235 respectively, have most frequently been isolated. Bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.